US 11,850,237 B2
Compounds and methods for treating influenza
Jean-Francois Rossignol, St. Petersburg, FL (US); and J. Edward Semple, Tampa, FL (US)
Assigned to Romark Laboratories L.C., Tampa, FL (US)
Filed by Romark Laboratories L.C., Tampa, FL (US)
Filed on Feb. 8, 2021, as Appl. No. 17/169,907.
Application 17/169,907 is a continuation of application No. 16/448,267, filed on Jun. 21, 2019, granted, now 10,912,768.
Application 16/448,267 is a continuation of application No. 15/814,949, filed on Nov. 16, 2017, granted, now 10,363,243.
Application 15/814,949 is a continuation of application No. 15/133,534, filed on Apr. 20, 2016, granted, now 9,820,975.
Application 15/133,534 is a continuation of application No. 14/658,409, filed on Mar. 16, 2015, granted, now 9,345,690.
Application 14/658,409 is a continuation of application No. 12/821,571, filed on Jun. 23, 2010, granted, now 9,023,877.
Claims priority of provisional application 61/220,891, filed on Jun. 26, 2009.
Prior Publication US 2021/0177809 A1, Jun. 17, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/426 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/675 (2006.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01); H01L 31/12 (2006.01); A61K 31/215 (2006.01); A61K 31/351 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/426 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2086 (2013.01); A61K 31/215 (2013.01); A61K 31/351 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/675 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); H01L 31/125 (2013.01); A61K 2300/00 (2013.01)] 42 Claims
 
1. A method of reducing a time to resolution of one or more symptoms of an influenza-like illness in a patient suffering from the influenza-like illness, but who does not test positive for Adenovirus, RSV, Influenza A, Parainfluenza 1, comprising administering to the patient a therapeutically effective amount of a compound selected from the group consisting of nitazoxanide, tizoxanide and a mixture thereof, or a pharmaceutically acceptable salt the compound,
wherein the one or more symptoms of the influenza-like illness are selected from the group consisting of nasal secretion, nasal obstruction, sneezing, sore throat, fever, cough, malaise, headache and chills.